BioMarin and Profluent partner on AI-designed enzyme therapies. Recommended companies. BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development pipeline. Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to identify molecules with the desired target activity and stability profiles, advancing selected candidates into preclinical testing. The creation and optimisation of therapeutic enzymes is typically a complex undertaking that requires extensive protein engineering and screening. Profluent will conduct the computational design work using the Profluent Protein Atlas, a dataset of more than 115 billion unique protein sequences and reportedly the world's largest protein sequence repository. BioMarin intends to use these foundation models to rapidly assess alternative protein structures before selecting candidates for further laboratory evaluation. BioMarin vice-president and metabolic conditions research head Pooja Agarwal said: "Profluent's AI models represent the kind of external innovation that can complement our own capabilities and help us move promising science forward faster. "By combining Profluent's approach to de novo protein design and optimisation with BioMarin's decades of expertise in enzyme therapies, we have an opportunity to identify promising candidates more efficiently for people with significant unmet need." Profluent CEO Ali Madani said: "BioMarin has one of the most credible track records in enzyme therapies, spending decades successfully advancing drugs through the clinic to improve the lives of patients. "We're excited to accelerate BioMarin's drug discovery pipeline and unlock new medicines by combining the strengths of our latest foundation models for protein design with their deep track record of getting therapies to patients." Founded in 2022 and based in Emeryville, California, Profluent develops biological foundation models intended for applications across medicine, agriculture, and other fields. The company's financial backers include AIX Ventures, Air Street Capital, Bezos Expeditions, Altimeter Capital, Insight Partners, Convergent Ventures, and Spark Capital. In April, BioMarin Pharmaceutical completed its acquisition of Amicus Therapeutics in an all-cash deal for a total equity value of nearly $4.8bn. Enter your email address so we can get in touch.

Profluent Partners with BioMarin to design novel medicines using AI. * Collaboration pairs Profluent's AI models with BioMarin's enzyme replacement therapy expertise to advance next-generation candidates for genetically defined conditions EMERYVILLE, Calif.-(BUSINESS WIRE)-Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs. Profluent's AI models represent the kind of external innovation that can complement its own capabilities and help Business Wire, Inc. move promising science forward faster. Share Developing and optimizing therapeutic enzymes is a complex process that can require extensive protein engineering and screening. Profluent will design and optimize enzyme candidates using its suite of proprietary protein language models, which use the Profluent Protein Atlas, the largest protein sequence dataset in the world composed of more than 115 billion unique sequences. BioMarin will leverage Profluent's AI models to rapidly explore protein designs to identify potential candidates with desired activity and stability profiles for further evaluation and advance the most promising candidates into preclinical testing. "Profluent's AI models represent the kind of external innovation that can complement our own capabilities and help us move promising science forward faster," said Pooja Agarwal, Ph.D., Vice President and Head of Metabolic Conditions Research at BioMarin. "By combining Profluent's approach to de novo protein design and optimization with BioMarin's decades of expertise in enzyme therapies, we have an opportunity to identify promising candidates more efficiently for people with significant unmet need." "BioMarin has one of the most credible track records in enzyme therapies, spending decades successfully advancing drugs through the clinic to improve the lives of patients," said Ali Madani, CEO of Profluent. "We're excited to accelerate BioMarin's drug discovery pipeline and unlock new medicines by combining the strengths of our latest foundation models for protein design with their deep track record of getting therapies to patients." About Profluent Profluent is the frontier AI lab for biology. Profluent builds powerful foundation models for all of life's molecules, unlocking solutions that transform medicine, agriculture, and beyond. Founded in 2022 and headquartered in Emeryville, CA, Profluent is backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more, visit www.profluent.bio or follow the company on LinkedIn, X, and YouTube.